Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | LDLR | P01130 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8392277 | 0.98 | EPHX1 (0.59) | EPHX1SIGMAR1NPC1RAB9AL3MBTL1 | |
| SCHEMBL931424 | 0.98 | EPHX1 (0.59) | EPHX1SIGMAR1NPC1RAB9AL3MBTL1 | |
| SCHEMBL8392768 | 0.96 | EPHX1 (0.52) | EPHX1SIGMAR1NPC1RAB9AL3MBTL1 | |
| SCHEMBL5392965 | 0.91 | — | — | |
| SCHEMBL8395918 | 0.88 | KDM4E (0.52) | EPHX1SIGMAR1KDM4EMAPK1HIF1A | |
| SCHEMBL8392406 | 0.86 | KDM4E (0.50) | EPHX1SIGMAR1KDM4EMAPK1HIF1A | |
| SCHEMBL8392716 | 0.86 | KDM4E (0.50) | EPHX1SIGMAR1KDM4EMAPK1HIF1A | |
| SCHEMBL19731592 | 0.84 | SIGMAR1 (0.56) | EPHX1SIGMAR1KDM4EMAPK1HIF1A | |
| SCHEMBL8392313 | 0.83 | KDM4E (0.52) | EPHX1SIGMAR1KDM4EMAPK1HIF1A | |
| SCHEMBL2091382 | 0.83 | KDM4E (0.41) | EPHX1SIGMAR1KDM4EMAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242886-A1 | Monocyclic diazodioxide based Bcl-2 protein antagonists related applications | RICERCA BIOSCIENCES, LLC. | 2004-12-02 | — | — | US | claimed |
| WO-2004099158-A1 | MONOCYCLIC DIAZODIOXIDE BASED BCL-2 PROTEIN ANTAGONISTS | RICERCA BIOSCIENCES, LLC. (US) | 2004-11-18 | — | — | WO | claimed |
| US-20210309882-A1 | COATING COMPOSITIONS | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2021-10-07 | — | — | US | disclosed |
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20040242886-A1 | Monocyclic diazodioxide based Bcl-2 protein antagonists related applications | RICERCA BIOSCIENCES, LLC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004099158-A1 | MONOCYCLIC DIAZODIOXIDE BASED BCL-2 PROTEIN ANTAGONISTS | RICERCA BIOSCIENCES, LLC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242886-A1 | Monocyclic diazodioxide based Bcl-2 protein antagonists related applications | BCL2A1, BCL2, BCL2L10 | EPHX1 4754/4885SIGMAR1 3097/4885NPC1 4513/4885 |
| US-20100222331-A1 | NEW COMPOUNDS | CCNA1, CCNY, MKI67 | EPHX1 563/4885SIGMAR1 452/4885NPC1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.